SRUC, which is the biggest provider of veterinary nursing, livestock husbandry and animal care training in Scotland, says it will offer a core veterinary programme to address existing shortages in veterinary provision, in areas such as rural veterinary practice, food production, food safety and animal and public health.
The College is first establishing a working group to progress the plans for the school. The group will be chaired by Professor Sir Pete Downes, former Principal and Vice-Chancellor of the University of Dundee.
Sir Pete will be joined by Sheila Voas, Chief Veterinary Officer for Scotland, former NFUS President Nigel Miller, SRUC Board member Jane Craigie, and Dr Kate Richards, who is a non-executive director on the SAC Commercial Board and currently the junior vice president of the RCVS, in line to become President in July.
Professor Caroline Argo, currently Dean of SRUC’s North Faculty, will lead the project for SRUC.
A report from BiGGAR Economics has found that the vet school could add £26 million GVA and 242 jobs to Scotland by 2030.
Professor Wayne Powell, Principal and Chief Executive of SRUC, said: “We are an ambitious institution with a bold vision for the future. This is a ground-breaking model to expand access to educational opportunities and broaden the range of potential students who would not ordinarily be able to attend a vet school. It will also help solve existing skills shortages across Scotland.
“We see a key role of the new vet school in sustaining primary agriculture and hence food and drink productivity, with the welfare of both livestock and companion animals at its heart. The school will produce champions for best-in-class animal welfare in support of these industries, which will help improve productivity, effectiveness, and sustainability.”
“Building on the excellent new facilities we have already announced for Aberdeen and Inverness, there is a lot of work still to be done, but we are ready to seize the opportunity.”
Vetbromide is presented as a 600mg double divisible tablet for both large and small dogs, and for greater flexibility with dose titration. Tablets are blister packed for ease of storage and dispensing, with a four-year unopened shelf life.
Alongside the launch, TVM has prepared a range of product support materials, including: product guidelines, treatment and monitoring guidelines, seizure management ‘lunch and learn’ sessions, and pet owner information.
TVM has also created a free e-learning tool which takes veterinary staff through the process of diagnosing, treating and monitoring dogs with suspected epilepsy.
Will Peel, product manager at TVM said: "The addition of Vetbromide to our epilepsy range allows vets more flexibility when treating epileptic patients. To further assist vets, we are also offering a wide range of free literature and in-practice support to ensure that veterinary staff are up to speed on such a common, yet at times complicated, topic.’
For more information, visit www.tvm-uk.com/epilepsy, or contact your TVM UK Territory Manager.
The association says the new Recognised Internships significantly enhance its existing programme which just listed available internships in equine practice.
Over the past year BEVA has worked with veterinary practices across the UK to develop a set of core skills that should be covered during an internship.
These standards sit alongside BEVA's existing Employment Toolkit which outlines what a new graduate should be considering when applying for a job (such as working hours, pay, CPD allowance).
Roger Smith, BEVA Junior Vice President said: “The new programme gives practices constructive guidance to provide a positive and inspirational introduction to a career as an equine vet, rather than the perhaps rushed and unintentionally unstructured, labour focused junior positions that have been experienced in times past.”
BEVA Chief Executive David Mountford said: “We are delighted that nearly 40 equine veterinary practices have already signed up to our Recognised Internships initiative.
"It is such a positive sign that as a profession we are all committed to ensuring we can offer the best start to those entering the profession.”
https://www.beva.org.uk/internships
Practices interested in joining the scheme should contact Fiona Cunnington - fiona@beva.org.uk
The poster gives information about things like lillies, chocolate, raisins, fertilisers, weedkillers and adders.
TVM will also be running its annual social media campaign about the most common spring dangers, giving practices digital content which they can share with clients.
To get a poster for your practice, contact your local TVM territory manager or visit https://www.tvm-uk.com/pet-dangers-order-free-display-materials-for-your-practice.
For those new to the club, the idea is that every two weeks, we pick an article in Veterinary Practice and invite the author to join us on VetSurgeon.org, so that you can ask questions and discuss the subject with one another.
As a bonus, you can claim time spent reading or participating in the discussion towards your annual CPD requirement (press the claim CPD button at the top right of the question thread).
To take part in this session, first read Ed's article here: https://www.veterinary-practice.com/article/endoscopic-retrieval-of-foreign-bodies.
Then come and post your questions or discussion points here: https://www.vetsurgeon.org/001/veterinary-clinical/small-animal/f/misc-clinical-discussions/30618/do-you-have-questions-about-endoscopic-retrieval-of-foreign-bodies-clinical-article-club
Bimeda has announced the launch of Butagran Equi (phenylbutazone), to join its range of analgesics and anti-inflammatories.
Bimeda says that Butagran Equi provides rapid onset of activity with the added convenience for horse owners or professionals of being presented as an easy-to-administer sweetened powder.
Indications include musculo-skeletal conditions that require relief from pain and a reduction in the associated inflammation, including lameness associated with osteoarthritic conditions, bursitis, laminitis and soft tissue inflammation.
Head of Bimeda technical services Padraig Hyland MVB said: "Butagran Equi is particularly suited where continued mobility is considered desirable. It is also of value in limiting post-surgical inflammation, myositis and other soft tissue inflammation and can be used as an anti-pyretic where this is considered advisable, such as in viral respiratory infections. And being a sweetened powder it's quite straightforward for horse owners to administer and dose as prescribed."
He added: "Butagran Equi follows the launch of a number of new products and is proof our desire to provide a comprehensive and relevant equine portfolio backed up with first class technical support."
The review, announced earlier this year, was recommended to RCVS Council by its Standards Committee following its exploration of the implications of new technologies for both animal health and welfare and veterinary regulation.
The main areas under consideration include the provision of 24-hour emergency cover and the interpretation and application of an animal being under the care of a veterinary surgeon.
The initial stages of this review had been drafted for Standards Committee to consider at its meeting on 9 September, where the outline timetable was also discussed.
Standards Committee Chair Melissa Donald, said: "This is set to become one of our most fundamental reviews of RCVS guidance in recent years.
"Considering the complexity of the issues in question, and their importance to animal owners and the professions alike, it is vital that we allow ourselves enough time to ensure this review is as thorough and comprehensive as possible.
"We have a clear responsibility to seek, understand and, where we can, accommodate the opinions and experiences of as many different people from within and around the professions and the public as possible. I would urge my fellow vets and vet nurses to please find some time to consider these issues very carefully over the coming weeks and months, and to send us their views."
The review will comprise several stages and is expected to take around 12 months to complete. The outline timetable, which may be subject to change, is as follows:
October 2019 – January 2020: six-week Call for Evidence, followed by independent qualitative analysis of all evidence received
February – March: Select Committee-style meetings and independent qualitative analysis of additional evidence gathered [NB this stage is subject to Standards Committee requirements, depending on the evidence gathered.]
April – June: Consider all evidence and draft any new policy
July – August: six-week public consultation on draft policy
September – October: independent review of consultation responses, and production of any proposals for change
November 2020: Finalise any proposals for change and publish any new guidance
To support and promote the various stages of the review the College is also planning a programme of stakeholder engagement, and will also provide regular updates on progress to both Council and the wider profession.
Members of the professions and the public will be able to follow the progress of the review via the RCVS website at: www.rcvs.org.uk/undercare
The association says that the day of lectures is mainly targeted at those who are starting on their path of ophthalmology, but old hands may also learn a few new tricks.
Topics will include how to get the most from the ophthalmic examination, diagnostics and what options there are for career growth in our specialty.
There will be live panel discussions to give attendees the opportunity to ask any questions they have.
Tickets costs £100+VAT for BrAVO members, £60+VAT for nurses and interns, and £40+VAT for students.
The deadline for registration is Tuesday 16th March at 5:00pm.
To book your ticket, visit: https://www.eventbee.com/v/bravo-spring-meeting-2021/event?eid=164693974#/tickets
The company's charity of the year is chosen by employees at its annual conference in October. Fundraising then begins the following January.
This year, fundraising activities included cake sales, 'wearing blue days' and dog shows. Others took a more energetic approach: a team from Tone Veterinary Centre in Taunton cycled the equivalent of Land’s End to John O’Groats on exercise bikes over a fortnight, raising £525, while groomer Ceri James from Petherton Vets in Cardiff climbed Ben Nevis.
Simon Innes, CVS Chief Executive said: "Each year, thousands of cats, dogs, small animals and horses rely on the hospitals, clinics and rehoming services run by Blue Cross so it was a very natural charity for us to support and the overwhelming winner of last year’s vote.
"Yet again, our teams have surpassed themselves by really getting behind our fundraising efforts and showing great creativity and dedication to the task. Judging by some of the photos, they also seem to have had a great deal of fun. We held a group-wide charity day during July in which all parts of the business participated. It was a fantastic event and really showed the power of collective fundraising."
Matt Cull, Deputy Director of Fundraising at Blue Cross, said: "The dedication from CVS to fundraise for our pets through many different activities is so inspiring. We are very grateful to all the teams for helping Blue Cross as the money raised will assist us in helping thousands of pets in need and support our other charitable activities, such as our education programmes and bereavement support service. Pets change lives and with this generous help, we can change theirs."
Photo: Simon Innes CVS Group Chief Executive; Diane James, Blue Cross; Piers Gibbon, CVS Conference compere
RVC researchers say that the VetCompass study is the largest ever carried out into dental disease in cats using veterinary clinical records.
The study investigated a sample of 18,249 cats randomly selected from a study population of 1,255,130 cats in the UK in 2019.
Periodontal disease was recorded in 15.2% of the sample making it the most common disorder.
The cat breeds with the highest annual levels of this diagnosis were Siamese (18.7%), Maine Coon (16.7%) and British Short Hair (15.5%) as well as crossbreeds (15.4%).
The average bodyweight of cats with periodontal disease (5.7kg) was higher than for cats without periodontal disease (5.5kg).
The risk of periodontal disease rose steeply as cats got older, with cats aged 9 to 12 years being 6.7 times more likely to have periodontal disease compared with cats aged under 3 years.
Cats with periodontal disease were much more likely to have a range of other health conditions compared to cats without periodontal disease (x 1.8 risk).
These conditions included cardiac dysrhythmia (x 2.3 risk), ear discharge (x 2.3 risk) and hairball/furball (x 2.3 risk).
The researchers say that these findings suggest that periodontal disease should be acknowledged as a leading health and welfare issue in cats, and highlight the need for greater dental care in cats as they age.
The study was supported by an award from the Kennel Club Charitable Trust and Agria Pet Insurance.
Virbac has announced a special promotion in which practices can earn a specialist ear instrument kit worth £100
The kit, which has been designed by Virbac vets in consultation with a number of veterinary dermatologists, is available with multiple purchases of the otitis treatment EasOtic, and the neutral pH glycotechnology ear cleaner Epi-Otic.
Product manager Chris Geddes MRCVS said: "Each kit contains a haemostat, ear forceps, 3 various cerumen scoops and a Spreulls ear-flushing needle. Basically it's the best ear equipment for daily use by practitioners. For a limited period we are giving away one set FOC with every purchase of 25 bottles of EasOtic and 25 bottles of Epi-Otic."
Chris added: "When it comes to treatment of otitis, we know that client compliance is a key issue. The award-winning design of EasOtic makes it an extremely easy product to use. The 'one pump' delivery system helps deliver more accurate dosing and minimises animal stress during application. This means that treatment courses are more likely to be completed, thus optimising results and client satisfaction all round."
For further information, please contact your local Virbac territory manager or call Virbac on 01359 243243.
The Royal College of Veterinary Surgeons has announced that Nick Stace has been appointed its Chief Executive and Secretary, and will take up his post on 3 September 2012.
Mr Stace leaves CHOICE, Australia's equivalent of consumer group Which?, after three and a half years as Chief Executive Officer. At CHOICE, Nick led the modernisation of the organisation, this year taking it to the number one spot as the most trusted media entity in Australia. A long-standing consumer champion, Nick also held the post of Deputy CEO at Which?, he was a director at Consumers' International and former Prime Minister Gordon Brown's Director of Strategic Communications.
RCVS President Jerry Davies said: "I am delighted that Nick Stace will be joining the College. With his impressive track-record, I believe that we have a Chief Executive who will lead the College into a new phase of modernisation and development. I am grateful to the Interview Panel, led by Council member Dr Barry Johnson, for all their hard work in securing this excellent appointment."
Nick Stace said: "It is an enormous privilege to be leading an organisation that seeks to ensure Britain has the best vets in the world. The College has a special place in the lives of every vet in the country, it also has a responsibility to animals and consumers to set high standards and ensure they are met. I look forward to helping the College continue to improve veterinary standards across the country and to lead the College through its next stage of development."
The role of Chief Executive and Secretary is a new one - previously the Registrar led the executive of the College. One of Nick Stace's first tasks will be to assist in recruitment of the Head of Legal Services/Registrar, a new role.
Royal Canin has announced the winner of its second annual Weigh In Club initiative: a 32kg 12 year old Beagle called Amber that lost 12.5kg, or 39% of her bodyweight.
The dog lost weight with the help of Veterinary Nurse Gabby Taylor from Wilson Vet Group in Bishop Auckland, and won a year's supply of Royal Canin food along with £500 of gift vouchers for her owner. Gabby also won £500 of vouchers for her efforts, as well as £1000 of equipment vouchers for her practice.
Gabby said: "Amber was referred to my weight clinic and we quickly started her on Royal Canin's Satiety Support diet. Over the course of six months, Amber lost weight healthily and reached her target weight of 19.5kg, making her a much happier dog."
117 dogs took part in the initiative, with the 12 finalists invited to appear in a Royal Canin 2013 'Weigh In Club Winners' calendar.
The competition, which is due to be repeated in 2013, was open to all vet practices which run weight clinics and use Royal Canin 'Obesity Management' and 'Satiety Support' diets as part of weight loss programmes run by Veterinary Nurses.
Ian Williams BVSc MRCVS, Royal Canin's Veterinary Support Manager, said: "With canine and feline obesity on the increase, Veterinary Nurses have an important role to play in educating pet owners and supporting the weight loss process. Choosing the right nutrition for the individual pet is a key part of a successful weight management programme, along with a tailored exercise plan, regular monitoring and commitment from the owner."
For more information about Royal Canin's diets, call the company's veterinary helpline on 0800 717800 or visit www.royalcanin.co.uk
Biogal Galed Labs has announced the launch of the PCRun Canine Babesia gibsoni molecular detection test kit.
Existing PCRun molecular detection test kits include one for canine Leptospira, Ehrlichia canis, Anaplasma platys, Parvovirus, Babesia canis, Leishmania, Feline Panleukopenia and Feline Mycoplasma haemofelis.
The company says that the major benefit of these tests is in having a PCR result inside 75 minutes, rather than waiting for up to a week for a result from a specialised laboratory.
For more information, see: http://www.biogal.co.il/about-biogal/pcrun
Defra's new measures include:
Eleven additional licences for badger control covering parts of Devon, Wiltshire, Somerset, Dorset and Cheshire. Licences have been granted for supplementary badger control in areas of Gloucestershire and Somerset which have completed their original four-year licences.
The relaunch of the Badger Edge Vaccination Scheme following suspension due to a global shortage of TB vaccine, with groups invited to submit expressions of interest and feedback on the criteria for the scheme.
A new bTB Advisory Service for farmers to provide advice on-farm and by phone or email to farmers in High Risk and Edge Areas on bTB biosecurity and risk-based trading, set to launch this autumn.
Tighter control of Inconclusive Reactors (IRs) in the High Risk and Edge Area, to come into force from 1 November.
British Veterinary Association (BVA) President Gudrun Ravetz said: "Today’s announcement sees 11 new licences issued and, while BVA supports badger culling as part of a comprehensive strategy for tackling bovine TB, we will continue to call on the Government to use the targeted and humane method of cage trapping and shooting only - rather than the current method of controlled shooting.
"As one of the many tools in the toolbox, we welcome the re-commencement of the Badger Edge Vaccination Scheme, particularly if used as a ‘firebreak’ to mitigate the spread of the disease into the low risk areas. The introduction of a TB Advisory Service will provide valuable additional support for farmers, who we’d encourage to continue working with local vets on biosecurity and herd health planning.
"Yet we are concerned that Government policy seems to have moved away from the original, evidence-based proposal of a six-week time limit for badger control within the open season, which enables an intensive, coordinated and effective operation in order to secure optimum disease control benefits.
"In terms of numbers, it is clear that badger population estimates have previously demonstrated considerable uncertainty and imprecision. It is critical that as accurate as possible population estimates, using an evidence-based methodology, are obtained and made openly available.
"We would urge clarity over cull timeframes, numbers and mid-cull review methodology to ensure that the progress made, enabling the application for Officially TB Free status, is not undermined."
Today’s Defra update follows a consultation on licensed badger control conducted at the start of 2017, to which the British Veterinary Association (BVA), British Veterinary Zoological Society (BVZS) and the Association of Government Veterinarians (AGV) submitted a formal, joint response.
Photo: Young Eurasian Badger (Meles Meles), by BadgerHero, CC BY-SA 3.0
DG Sanco, the EU Directorate General for Health and Consumers, has launched a worldwide photo competition to mark World Vet Year: 'Vets in your daily life'
Entries need to be photos of a vet (or vets) at work or in any situation which shows the diverse nature of the job. Five winners will win 1000 Euros worth of photographic equipment. The overall winner will win an additional 2000 Euros worth of photographic equipment. All winners will also be given travel and accommodation for the awards ceremonies in Paris and Brussels.
Anyone (except for employees of the European Institutions, and their families) can enter the competition, which closes on 31st March 2011. More details can be found at: www.vetsinyourdailylife.org.
Here's the promotional video for the competition:
The company says the return to a ‘new normal’ post-lockdown provides a significant opportunity for practices to apply a renewed focus to preventative healthcare, recommending parasiticides as a way to improve animal welfare and generate practice revenue, which is vital for economic recovery.
Caitrina Oakes, Vetoquinol Managing Director UK and Ireland, said: “With many pet owners spending more hours than ever with their pets during lockdown, companion animal parasiticides have never been more important – making Profender and Drontal highly relevant in the current environment.”
She added: “It’s a very challenging time for many veterinary practices as everyone adapts to the post-COVID world. I’m looking forward to seeing how the passion and ambition we bring to our brands helps Profender and Drontal to grow and helps us to better serve the needs of the veterinary community, both now and in the future.”
Up to date information on the brands and their distribution can be found on the Vetoquinol website, www.vetoquinol.co.uk, by calling 01280 814500, or practices can contact their Vetoquinol Territory Manager directly.
The RCVS Disciplinary Committee has dismissed a case against a London-based veterinary surgeon, having found charges related to fraudulent registration not proved.
Miss Maria Becerra Parga was charged with fraudulently entering her name on the Register of Veterinary Surgeons, by submitting a registration application in 2005 that contained a forged certificate of good standing from the Distinguished Official Veterinary Association of Lugo, Spain.
The Committee said that, in order to conclude Miss Becerra Parga had acted dishonestly, it needed to be sure that when she submitted the certificate to the RCVS she knew it was not genuine.
Miss Becerra Parga admitted that she did not make any application for the certificate directly to the Lugo Association. She accepted that the certificate she supplied to the College (the number of which was genuine and corresponded to a male veterinary surgeon registered in Spain) was a forgery, and that it contained a reference to her degree, a statement of good conduct, and was dated before she had a need for it; however, she said, this had been given to her by a friend and veterinary colleague and she had understood that she had been given a temporary membership of the Lugo Association for the purpose of registering with the RCVS. She also said that she had left these arrangements to her colleague and assumed that the document she had been given was genuine.
Her colleague, called as a witness by the College, said that Miss Becerra Parga had admitted the fraud to her and she denied that she had given the certificate to Miss Becerra Parga. Her friend said that she gave no more than general guidance because she knew that Miss Becerra Parga would be guided by a UK company that would arrange for her registration with the RCVS and through which she would be employed. She thought it possible that she had told Ms Becerra Parga that she needed a letter of recommendation, but she was not sure.
After careful consideration, the Committee preferred the evidence of Miss Becerra Parga and found her account to be "consistent with her naivety, inexperience and trusting nature" and "was sure that she did not forge the document herself". It found that to the extent that Miss Becerra Parga read the certificate at all when given it, she obviously did not notice its date or significance. The Committee was not able to say who was responsible for forging the certificate.
The Committee also dismissed an argument RCVS Counsel put forward, that Miss Becerra Parga had neither offered nor made payment for the certificate, and that she had forged the certificate to avoid a payment. The Committee said it did not find it credible that a veterinary surgeon, in work with a supportive family, who obviously was easily able to obtain proof of her good character directly from the university if necessary, would have jeopardised her entire career by forging the document, let alone for a small financial advantage.
The Committee directed that the charges be dismissed.
Pfizer Animal Health has launched Poulvac, the first modified live vaccine against E.coli in chickens.
The company claims that the vaccine, which can be used from one day of age, is set to bring major benefits in safeguarding the health of broilers, pullets for egg laying and breeding stock.
According to Pfizer, E.coli is one of the most significant bacterial pathogens found in chicks during the first week, leading to problems throughout the life of a flock including inferior performance, lack of uniformity and increased mortality. It is a costly, widespread problem for the UK poultry industry.
The vaccine was developed from research beginning in the 1990s at the Government's veterinary laboratories at Weybridge (now AHVLA) in the UK, employing genome technology to produce an avirulent strain of E.coli that induces protective immunity to the pathogenic strains of the bacteria.
The vaccine is completely non-pathogenic, and does not persist in the bird or the environment for any significant period of time. A gene deletion in its development restricts in vivo replication and leaves behind activated macrophages ready to respond to pathogenic E.coli strains.
Dr Stuart Andrews, poultry technical manager of Pfizer in the UK and Ireland said: "Poulvac E. coli provides broad cross protection against the key serotypes of E. coli infecting chickens. It is the only modified live, nonreactive vaccine proven to meet the European regulatory requirements for efficacy and safety.
"Trials have confirmed that Poulvac E.coli does not persist in the bird and proves to be self-limiting. The vaccine can survive in the environment for only a short time, and spread to in-contact birds is also limited."
The vaccine is administered as a coarse spray with onset of immunity 14 days afterwards and duration of immunity for up to 12 weeks. It can be used from day-old up to six weeks before the onset of lay, and has a nil day withdrawal period.
In the USA where Poulvac E coli has been available for six years field experience has shown the considerable benefits. In the Midwest where average layer mortality at 50 weeks of age was 2.31 per cent, this was reduced to 1.51 per cent with three doses of the vaccine*. In Eastern USA flock mortality compared with five previous flocks was reduced from over three per cent to one per cent.
A field trial in the USA with more than 300,000 broiler breeders vaccination before lay reduced mortality from 2.8 to 1.9 per cent - with only two out of 28 flocks needing antibiotic treatment compared with 13 of the 28 unvaccinated flocks.
On a broiler field trial in Georgia over four million birds were vaccinated with Poulvac E. coli at hatch. The vaccinated birds had a better feed conversion (1.79 against 1.84 for the controls) and with condemnations at the processing plant down from 1.22 to 0.73 per cent the result was a lower production cost of 0.51¢ per lb.
In another broiler trial covering more than two million birds in Arkansas livability was improved from 95.20 to 95.77 per cent and feed conversion improved from 1.95 to 1.90, gaining 0.45¢ per lb.
* Pfizer says it is important to note that in these studies carried out in the USA more than one dose of the vaccine was often administered. A single vaccination is licensed in the Summary of Product Characteristics however, where clinical disease requires and at the discretion of a veterinary surgeon, the vaccination schedule may be re-started as there is no contra-indication on the SPC.
Elanco Companion Animal Health has announced that its Duvaxyn IE and IE-T Plus vaccines have been licensed for active immunisation against OIE recommended clade 1 and clade 2 equine influenza strains, the first vaccines to be so licensed.
The company says the updated license is a result of a recent challenge study which demonstrated the ability of Duvaxyn IE-T Plus equine influenza vaccine to induce cross protection against clade 2 strain A/equi-2/Richmond/1/07 (H3N8) two weeks after two doses of the primary course1 were given. Cross-protection was further supported by another study2 measuring serum antibody response to the Richmond '07 strain 52 weeks after the three dose primary vaccination course.
The OIE (World Organisation for Animal Health) updated its equine influenza vaccine recommendations in 2010 to reflect the fact that all field strains characterised through 2008 and 2009 were of clade 1 or 2 of the Florida sub-lineage. The antigenic difference between viruses of these clades could potentially compromise the effectiveness of vaccines containing a representative of a single clade3.
Anna Jackson, national veterinary manager for Elanco Companion Animal Health UK, said: "Whilst no vaccine has been updated to match the current OIE recommendations, the results of our challenge study and subsequent licence update provide reassurance that horses vaccinated with Duvaxyn will be protected against clinical signs of disease caused by currently circulating strains of equine influenza, including those the OIE has identified as being of concern.
"Further reassurance is also given with the confirmation in our study that Duvaxyn IE-T Plus elicits a cell mediated immune response, recognised to play an important role to aid in viral clearance and further enhances protection against strains circulating in the field." 4
The live virus challenge study, conducted by the Animal Health Trust, involved two groups of EIV seronegative horses. The first group, consisting of seven vaccinates, were given two doses of Duvaxyn IE-T Plus, 28 days apart, and challenged with A/equi-2/Richmond/1/07 (H3N8) virus strain 14 days after the second vaccination. The second group of unvaccinated horses was challenged at the same time. Duvaxyn IE-T Plus caused a statistically significant reduction in both clinical signs of the disease and in viral shedding.
Duvaxyn IE-T Plus is the only inactivated whole virus carbomer adjuvanted equine influenza vaccine in the UK. According to Elanco, experts in the field of human vaccination have expressed the view that whole virus vaccines have the potential to induce a stronger and more broadly based response to circulating influenza strains than those contained in sub-unit vaccines because of the presence of the full set of virus proteins including the conserved nucleoprotein, which shows no antigenic drift, in the vaccine5.
References
In the Voice of the Profession survey, 52% of nearly 700 veterinary surgeons said it was their biggest concern, more than double the number that said so two years ago. The figure was even higher amongst veterinary surgeons working in companion animal practice, with 66% citing it as a major issue.
The BVA is highlighting these statistics and encouraging veterinary teams to talk to clients about responsible dog breeding and buying during this year's Puppy Awareness Week, which runs till 10th September.
The BVA and the Kennel Club run Canine Health Schemes which screen dogs for inherited conditions including hip and elbow dysplasia, hereditary eye disease, and Chiari-malformation/Syringomyelia. Dog owners and breeders can use the results to make more informed breeding decisions and help improve the health of breeds susceptible to debilitating or life-limiting inherited conditions.
Pre-breeding testing and screening are not just for purebred pedigree dogs - screening is also important for crossbreed dogs, such as Labradoodles and Cockerpoos, which are becoming increasingly popular.
BVA President Gudrun Ravetz said: "With breeding and hereditary defects emerging as the number one animal health and welfare concern for vets, it is more important than ever to screen before breeding dogs. Vets in practice regularly see cases of inherited conditions such as hip dysplasia and eye problems that are debilitating and distressing for dogs.
"The good news is that we have schemes and tests in place that help breeders and owners make sound judgements about responsible breeding. The BVA/KC Canine Health Schemes and Kennel Club DNA testing services are critical tools for breeders. Anyone thinking of breeding from their dog or thinking about buying a puppy should ask their vet about available health schemes and how they can be used to inform their decisions."
During Puppy Awareness Week, BVA is also working with the Animal Welfare Foundation to promote the use of the Puppy Contract, which contains a section for the breeder to fill out about any health screening or DNA results to offer reassurance to owners.
BVA, in partnership with ITN Productions, has developed a 4-minute film on responsible dog breeding and buying that can be played in practice waiting rooms or on social media channels, which also explains the process and benefits of the Canine Health Schemes.
More details about the BVA/KC Canine Health Schemes can be found at: https://www.bva.co.uk/Canine-Health-Schemes/
Photo: By DodosD - Own work, CC BY-SA 3.0, Link
The survey of 50 vets carried out in May this year1 found that only half of them are recommending strangles vaccination to their clients.
They also felt that horse owners could be doing more to combat the disease.
Less than half of vets questioned believed that yards and premises operated good biosecurity measures prior to a strangles outbreak, yet 85% brought in more stringent biosecurity after an outbreak, when it was too late.
Dechra says that vets and horse owners can help combat the estimated 300 outbreaks of strangles each year with the following steps:
Sara Barker BVSc CertAVP(EM) MRCVS, equine field support manager at Dechra, said: “Strangles is one of the most common equine infectious diseases both in the UK and worldwide and a multi-factor approach is key to tackling the disease.
"Strangles vaccination is recommended, alongside good biosecurity, quarantine measures and regular temperature checking.
"By working together, vets and horse owners can help to keep horses healthy and prevent the spread of strangles.”
Reference
Vetoquinol has announced the launch of Equistro Flexadin UCII, an equine joint supplement.
Equistro Flexadin UCII contains a new ingredient, UC-II, which the company claims is one of the most effective and influential ingredients available that aids and supports healthy joint function.
To celebrate the launch of Flexadin UCII Vetoquinol is offering a £10 money off voucher available through purchases of Horse & Hound magazine starting from November 10th.
Caitríona Mullin, Equine Product Manager at Vetoquinol UK Ltd said: "We are very excited about the launch of Flexadin UCII in the UK and Ireland, we have already received excellent feedback from our German and French colleagues. Flexadin UCII is a product that will further enhance our premium range of equine supplements formulated specifically for the performance horse."
The association says the qualification will help vets conduct clinical research relating to their work - in particular vets working in practice. It is aimed at people who already have any accredited postgraduate certificate (60 credits at Level 7) relevant to some aspect of veterinary medicine or surgery and are keen to develop a deeper understanding of their research topic.
The Masters starts with online study into the principles of clinical research, which students then apply to their own research project, based on a further 1,200 study hours that could be flexibly achieved in two years of part-time study or up to five years, depending on the project type and an individual’s availability.
Lucie Goodwin, BSAVA Head of Education (pictured right), said: "For those vets who have already completed a postgraduate certificate it is an opportunity to develop their skills further, partake in research and collect valuable data from the field. So much of the published data in veterinary journals is based upon a referral population and this may not necessarily reflect what truly happens in clinical practice."
She added: "The BSAVA Masters is designed to appeal to vets who want to undertake research alongside their job role, without having to commit to a full-time programme of study."
Students will be allocated a ‘matched’ supervisor to provide project advice and guidance, plus the BSAVA team will be on hand to ensure ongoing support and encouragement.
Johanna Forsyth, senior veterinary technical manager with the diagnostic laboratory Avacta Animal Health, joined the Masters programme when it launched in 2016. She said: "The thing that has given me the most satisfaction from taking part in this programme is the way my views have changed. I look at things I wrote a little while back and think: 'Did I really say that?'. You become so absorbed in the project that you don’t notice how your understanding of the topic has grown. It’s so subtle, we haven’t been force-fed anything - it’s just like osmosis."
For more information, please contact masters@bsava.com or visit the website https://www.bsava.com/Education/Masters
Dechra Veterinary Products is warning veterinary professionals it is experiencing supply issues with Oxyglobin, Haemoglobin Glutamer-200.
Dechra has supplied Oxyglobin under an exclusive UK distributor agreement with Biopure Corporation since 2002. In 2009, the assets of Biopure Corporation were acquired by OPK Biotech, which has its headquarters in Cambridge, MA, USA. OPK Biotech is working to resume manufacture of Oxyglobin as soon as possible but it is not expected this will happen until well into 2011.
Bob Parmenter, Managing Director of Dechra Veterinary Products, said: "Unfortunately we are now out of stock of Oxyglobin and, due to the supplier's manufacturing issues, we are unlikely to receive new supplies in the immediate future. I would like to apologise to veterinary professionals for any inconvenience this will cause to their practice but unfortunately this situation is out of our control. We have written to all our Oxyglobin customers to inform them of the position and will keep in contact to advise them when the situation has changed."
Dechra is advising veterinary professionals that the Pet Blood Bank may be able to offer an alternative product, while Oxyglobin is out of stock. The Pet Blood Bank can be contacted on 01509 232 222, Monday to Friday between 0830 and 1830. The organisation offers a same day and next day delivery service, along with an advice line. Full details of products and services are available by logging on to www.petbloodbank.org